|
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Clinical research trials and Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer. Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer  Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
For Condition: Non-small cell lung cancer,malignant mesothelioma,pulmonary carcinoid tumor,lung metastases,Small Cell Lung Cancer,thymoma and thymic carcinoma
Status: No longer recruiting
Sponsor(s): Jonsson Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
Details: OBJECTIVES: - Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. - Determine the efficacy of this treatment, in terms of local control, in these patients. - Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of a primary or secondary intrathoracic malignancy - Any cell type or origin - Involving the intrapulmonary, mediastinal, or pleural/chest wall - Inoperable primary or metastatic cancer to the lung - Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy) - Single or multiple lesions that are non-contiguous with vital structures or organs such as: - Trachea - Heart - Aorta - Great vessels - Esophagus - Less than 5 cm in largest dimension - Accessible via percutaneous transthoracic route PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Coagulation profile normal Renal: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertSuh, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000068889; UCLA-9908024,NCI-G01-2011
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00024076
Other Thymoma And Thymic Carcinoma Studies:
1. Phase III Randomized Study of Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion for Smoking Cessation and Prevention of Relapse in Participants Who Currently Smoke
2. Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer
3. Iressa/Docetaxel in Non-Small-Cell Lung Cancer
4. Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer
5. Vaccine Therapy in Treating Patients With Gastric Cancer, Non-Small Cell Lung Cancer, Prostate, or Ovarian Cancer
Related Studies:
Other thymoma and thymic carcinoma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
|
|
|
|
|
|
|
|
